



**Press Release**

Thursday, April 26, 2012



Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## **Strides acquires US FDA approved Sterile Formulations facility**

- **Provides immediate incremental capacity**

---

**April 26, 2012 Bangalore:** Strides Arcolab Limited today announced that, as part of its well articulated strategy to build and expand the core injectable business, Agila Specialities (a wholly owned subsidiary of Strides) has acquired a US FDA approved Sterile Formulations facility situated at Hosur, Tamil Nadu from Star Drugs and Research Labs Limited.

The facility manufactures a wide range of injectable formats. The liquid vials unit with a capacity of 97 million units has recently been approved by the US FDA. The facility is located at Hosur, Tamil Nadu and is in close proximity to the Strides new Sterile complex, in the outskirts of Bangalore.


The consideration for the facility is approximately Rs. 1250 million and is being funded from cash in hand and internal accruals.

**Rationale for acquisition:**

- Provides immediate incremental capacity as the existing capacities are fully committed due to drug shortages of Sterile injectables worldwide
- Provides significant time to market advantage as setting up and commercialising a Greenfield project will take 4-5 years
- Expedited Flow of product commercialization.

Commenting on the development, Mr. Arun Kumar, Group CEO of Strides said “This timely acquisition brings into our fold, an asset which is of immediate importance given the demand for Sterile injectables worldwide”.

Strides expects to ship products to the USA from this facility starting Q3 '12.



## **About Agila Specialties**

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

## **About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com).

For further information, please contact:

<b><u>Strides</u></b>	<b><u>PR Consultancy</u></b>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice   Weber Shandwick
Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)	Mahesh Nair, +91 9880376648 <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a>
	Kaveri Mandanna, +91 90089 59697 <a href="mailto:kaveri@corvoshandwick.co.in">kaveri@corvoshandwick.co.in</a>

